Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor

@article{Yehezkel2010LongactingIA,
  title={Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor},
  author={Einat Yehezkel and Doron Weinstein and Matthias Simon and Rive Sarfstein and Z. V. I. Laron and Hendrikje Werner},
  journal={Diabetologia},
  year={2010},
  volume={53},
  pages={2667-2675}
}
Insulin analogues were developed to improve the pharmacological properties of injected insulin and to better mimic endogenous insulin output. However, certain insulin analogues have been suggested to display IGF-I-like biological activities. Furthermore, several recent epidemiological studies have suggested a potential increase in cancer risk for treatment of diabetes patients with long-acting analogue insulin glargine (A21Gly,B31Arg,B32Arg human insulin). Additional studies, however, reported… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

Insulin glargine use and short-term cancer incidence—a population-based follow-up in Sweden

  • JM Jonasson, R Ljung, M Talback, B Haglund, S Gubdojornsdottir, G Steineck
  • Diabetologia
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…